nach oben

Erschienen in:

01.01.2021 | Systematic Review

Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update

verfasst von: Kirk E. Evoy, Sarvnaz Sadrameli, Jillian Contreras, Jordan R. Covvey, Alyssa M. Peckham, Megan D. Morrison

Erschienen in: Drugs | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

A 2017 systematic review (SR) identified 59 studies examining gabapentinoid (pregabalin and gabapentin) misuse/abuse. Evidence of gabapentinoid misuse/abuse has since grown substantially.

Objective

Update previous SR and describe new insights regarding gabapentinoid abuse.

Methods

A SR of PubMed was conducted to identify studies published from 7/29/2016–8/31/2020. Four searches were performed using the following terms: “gabapentin [MeSH] OR pregabalin [MeSH] OR gabapentinoid” AND one of the following substance misuse/abuse-related terms: “substance-related disorders [MeSH]”, “overdose”, “abuse”, or “misuse”. Clinicaltrials.gov and the Cochrane Library database were searched to identify ongoing studies or similar SRs. Reference lists of included studies were reviewed to identify additional literature. All studies with novel data related to pregabalin and/or gabapentin abuse, misuse, or overdose conducted during the study period were included. Articles not written in English, review articles, and animal studies were excluded.

Results

Fifty-five studies were included (29 [52.7%] from North America, 17 [30.9%] Europe, 6 [10.9%] Asia, and 3 [5.5%] Australia). Forty-six observational studies and 10 case reports/series were included (one manuscript included both). Twenty (36.4%) studied gabapentin only, 18 (32.7%) pregabalin only, and 17 (30.9%) both pregabalin/gabapentin. These studies corroborate findings from the previous SR that gabapentinoids are increasingly abused or misused to self-medicate, that gabapentinoids can produce desirable effects alone but are often used concomitantly with other drugs, and that opioid use disorder is the greatest risk factor for gabapentinoid abuse. While the original SR identified the largest studies having been published in Europe, this review identified several more generalisable US studies that have subsequently been conducted. The most concerning finding was increased evidence of associated patient harm, including increased hospital utilisation and opioid-related overdose mortality risk.

Conclusion

Evidence suggests that gabapentinoid misuse/abuse represents a growing trend that is causing significant patient harm. Prescribers should exercise appropriate caution with use in high-risk populations and monitor for signs of misuse or abuse.

Evoy KE, Morrison M, Saklad SR. Pregabalin and gabapentin abuse: a systematic review. Drugs. 2017;77(4):403–26.CrossRefPubMed

Peckham AM, Ananickal MJ, Sclar DA. Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance. Risk Manag Healthc Policy. 2018;11(1):109–16.CrossRefPubMedPubMedCentral

Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin—results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66(9):947–53.CrossRefPubMed

Chiappini S, Schifano F. A decade of gabapentinoid misuse: an analysis of the European Medicines Agency’s ‘Suspected Adverse Drug Reactions’ database. CNS Drugs. 2016;30(7):647–54. https://doi.org/10.1007/s40263-016-0359-y.CrossRefPubMed

Kapil V, Green JL, Le Lait MC, Wood DM, Dargan PI. Misuse of the c-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78(1):190–1.CrossRefPubMed

Peckham AM, Fairman KA, Sclar DA. All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: a retrospective cohort analysis of a commercially insured US population. Drug Saf. 2018;41(2):213–28. https://doi.org/10.1007/s40264-017-0595-1.CrossRefPubMed

Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14(10):e1002396. https://doi.org/10.1371/journal.pmed.1002396.CrossRefPubMedPubMedCentral

Gomes T, Greaves S, van den Brink W, Antoniou T, Mamdani MM. Pregabalin and the risk of opioid-related death: a nested case-control study. Ann Intern Med. 2018;169(10):732–4.CrossRefPubMed

Abrahamsson T, Berge J, Öjehagen A, Håkansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment—a nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58–64. https://doi.org/10.1016/j.drugalcdep.2017.01.013.CrossRefPubMed

10.

Al-Husseini A, Wazaify M, Van Hout MC. Pregabalin misuse and abuse in Jordan: a qualitative study of user experiences. Int J Ment Health Addict. 2018;16(3):642–54. https://doi.org/10.1007/s11469-017-9813-4.CrossRefPubMed

11.

Al-Husseini A, Abu-Farha R, Wazaify M, Van Hout MC. Pregabalin dispensing patterns in Amman-Jordan: an observational study from community pharmacies. Saudi Pharm J. 2018;26(3):306–10. https://doi.org/10.1016/j.jsps.2018.01.012.CrossRefPubMedPubMedCentral

12.

Al-Husseini A, Abu-Farha R, Van Hout MC, Wazaify M. Community pharmacists experience of pregabalin abuse and misuse: a quantitative study from Jordan. J Subst Use. 2019;24(3):273–9. https://doi.org/10.1080/14659891.2018.1554716.CrossRef

13.

Blackmer J, Lindahl E, Strahl A, Schadler A, Freeman PR. Regulating gabapentin as a drug of abuse: a survey study of Kentucky community pharmacists. J Am Pharm Assoc. 2019;59(3):379–82. https://doi.org/10.1016/j.japh.2018.12.018.CrossRef

14.

Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-derived data on gabapentin diversion and misuse, 2002–2015: diversion rates and qualitative research findings. Pharmacoepidemiol Drug Saf. 2017;26(9):1083–6. https://doi.org/10.1002/pds.4230.CrossRefPubMed

15.

Cairns R, Schaffer AL, Ryan N, Pearson SA, Buckley NA. Rising pregabalin use and misuse in Australia: trends in utilisation and intentional poisonings. Addiction. 2019;114(6):1026–34. https://doi.org/10.1111/add.14412.CrossRefPubMed

16.

Crossin R, Scott D, Arunogiri S, Smith K, Dietze PM, Lubman DI. Pregabalin misuse-related ambulance attendances in Victoria, 2012–2017: characteristics of patients and attendances. Med J Aust. 2019;210(2):75–9. https://doi.org/10.5694/mja2.12036.CrossRefPubMed

17.

Dahlman D, Abrahamsson T, Kral AH, Hakansson A. Nonmedical use of antihistaminergic anxiolytics and other prescription drugs among persons with opioid dependence. J Addict. 2016;2016:9298571. https://doi.org/10.1155/2016/9298571.CrossRefPubMedPubMedCentral

18.

Daly C, Griffin E, Ashcroft DM, Webb RT, Perry IJ, Arensman E. Intentional drug overdose involving pregabalin and gabapentin: findings from the National Self-Harm Registry Ireland, 2007–2015. Clin Drug Investig. 2018;38(4):373–80. https://doi.org/10.1007/s40261-017-0616-y.CrossRefPubMed

19.

Dart RC, Bartelson BB, Severtson SG, Bau G, Green JL. Increasing abuse of gabapentin and pregabalin as reported to US poison centers 2006 through 2014. Drug Alcohol Depend. 2017;2017(171):e51. https://doi.org/10.1016/j.drugalcdep.2016.08.152.CrossRef

20.

Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France. Br J Clin Pharmacol. 2019;85(6):1260–9. https://doi.org/10.1111/bcp.13892.CrossRefPubMedPubMedCentral

21.

Elliott SP, Burke T, Smith C. Determining the toxicological significance of pregabalin in fatalities. J Forensic Sci. 2017;62(1):169–73. https://doi.org/10.1111/1556-4029.13263.CrossRefPubMed

22.

Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS). Res Social Adm Pharm. 2019;15(8):953–8. https://doi.org/10.1016/j.sapharm.2018.06.018.CrossRefPubMed

23.

Evoy KE, Yin SL. Pharmacist awareness and attitudes regarding gabapentinoid abuse. TSHP J. 2018;17(1):12–5.

24.

Geller AI, Dowell D, Lovegrove MC, Rose KO, Weidle NJ, Budnitz DS. US Emergency department visits resulting from nonmedical use of pharmaceuticals, 2016. Am J Prev Med. 2019;56(5):639–47.CrossRefPubMedPubMedCentral

25.

Hargrove SL, Bunn TL, Slavova S, et al. Establishment of a comprehensive drug overdose fatality surveillance system in Kentucky to inform drug overdose prevention policies, interventions and best practices. Inj Prev. 2018;24(1):60–7. https://doi.org/10.1136/injuryprev-2016-042308.CrossRefPubMed

26.

Haukka J, Kriikku P, Mariottini C, Partonen T, Ojanperä I. Non-medical use of psychoactive prescription drugs is associated with fatal poisoning. Addiction. 2018;113(3):464–72. https://doi.org/10.1111/add.14014.CrossRefPubMed

27.

Ianni F, Aroni K, Gili A, et al. GC-MS/MS detects potential pregabalin abuse in susceptible subjects’ hair. Drug Test Anal. 2018;10(6):968–76. https://doi.org/10.1002/dta.2347.CrossRefPubMed

28.

Lyndon A, Audrey S, Wells C, et al. Risk to heroin users of polydrug use of pregabalin or gabapentin. Addiction. 2017;112(9):1580–9. https://doi.org/10.1111/add.13843.CrossRefPubMedPubMedCentral

29.

Macleod J, Steer C, Tilling K, et al. Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records. PLoS Med. 2019;16(11):e1002965. https://doi.org/10.1371/journal.pmed.1002965.CrossRefPubMedPubMedCentral

30.

Mutschler J, Gastberger S, Baumgartner MR, et al. Pregabalin use among opioid-addicted patients in Switzerland. J Clin Psychiatry. 2016;77(9):1202–3. https://doi.org/10.4088/JCP.15l10296.CrossRefPubMed

31.

Nahar LK, Murphy KG, Paterson S. Misuse and mortality related to gabapentin and pregabalin are being under-estimated: a two-year post-mortem population study. J Anal Toxicol. 2019;43(7):564–70. https://doi.org/10.1093/jat/bkz036.CrossRefPubMed

32.

Peckham AM, Fairman KA, Sclar DA. Prevalence of gabapentin abuse: comparison with agents with known abuse potential in a commercially insured US population. Clin Drug Investig. 2017;37(8):763–73. https://doi.org/10.1007/s40261-017-0530-3.CrossRefPubMed

33.

Peckham AM, Evoy KE, Covvey JR, Ochs L, Fairman KA, Sclar DA. Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured US population. Pharmacotherapy. 2018;38(4):436–43. https://doi.org/10.1002/phar.2096.CrossRefPubMed

34.

Piper BJ, Suarez MJ, Piserchio JP, et al. Illicit and prescription drug misuse as reported to the maine diversion alert program. Forensic Sci Int. 2018;285:65–71. https://doi.org/10.1016/j.forsciint.2018.01.025.CrossRefPubMed

35.

Sason A, Adelson M, Schreiber S, Peles E. Pregabalin misuse in methadone maintenance treatment patients in Israel: prevalence and risk factors. Drug Alcohol Depend. 2018;189:8–11. https://doi.org/10.1016/j.drugalcdep.2018.04.025.CrossRefPubMed

36.

Slavova S, Miller A, Bunn TL, et al. Prevalence of gabapentin in drug overdose postmortem toxicology testing results. Drug Alcohol Depend. 2018;186:80–5. https://doi.org/10.1016/j.drugalcdep.2018.01.018.CrossRefPubMed

37.

Smolina K, Crabtree A, Chong M, et al. Patterns and history of prescription drug use among opioid-related drug overdose cases in British Columbia, Canada, 2015–2016. Drug Alcohol Depend. 2019;194:151–8. https://doi.org/10.1016/j.drugalcdep.2018.09.019.CrossRefPubMed

38.

Snellgrove BJ, Steinert T, Jaeger S. Pregabalin use among users of illicit drugs: a cross-sectional survey in Southern Germany. CNS Drugs. 2017;31(10):891–8. https://doi.org/10.1007/s40263-017-0467-3.CrossRefPubMed

39.

Tamburello AC, Kathpal A, Reeves R. Characteristics of inmates who misuse prescription medication. J Correct Health Care. 2017;23(4):449–58. https://doi.org/10.1177/1078345817727730.CrossRefPubMed

40.

Tharp AM, Hobron K, Wright T. Gabapentin-related deaths: patterns of abuse and postmortem levels. J Forensic Sci. 2019;64(4):1105–11. https://doi.org/10.1111/1556-4029.14021.CrossRefPubMed

41.

Tomko JR, Prasad KM, Kubas S, Simpson T. The association of gabapentin use and dose with substance use disorders prior to inpatient mental health treatment: a cross-sectional study. Prim Care Companion CNS Disord. 2018;20(4):1802291. https://doi.org/10.4088/PCC.18m02291.CrossRef

42.

Van Baelen L, De Ridder K, Antoine J, Gremeaux L. Utilisation of gabapentin by people in treatment for substance use disorders in Belgium (2011–2014): a cross-sectional study. Arch Public Health. 2018;76:17. https://doi.org/10.1186/s13690-018-0254-8.CrossRefPubMedPubMedCentral

43.

Vickers Smith R, Boland EM, Young AM, et al. A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky. Psychol Addict Behav. 2018;32(1):115–21. https://doi.org/10.1037/adb0000337.CrossRefPubMed

44.

Wagner E, Raabe F, Martin G, et al. Concomitant drug abuse of opioid dependent patients in maintenance treatment detected with a multi-target screening of oral fluid. Am J Addict. 2018;27:407–12. https://doi.org/10.1111/ajad.12737.CrossRef

45.

Wazaifya M, Aboodb E, Tahainehc L, Albsoul-Younesa A. Jordanian community pharmacists’ experience regarding prescription and nonprescription drug abuse and misuse in Jordan—an update. J Subst Use. 2017;22(5):463–8. https://doi.org/10.1080/14659891.2016.1235734.CrossRef

46.

Banker K, Ruekert L, Hasan S. Compulsive gabapentin abuse despite lack of desirable effects: a case report. J Subst Use. 2017;22(6):661–3. https://doi.org/10.1080/14659891.2016.1271042.CrossRef

47.

Driot D, Chicoulaa B, Jouanjus E, Dupouy J, Oustric S, Lapeyre-Mestre M. Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history. Therapie. 2016;71(6):575–8. https://doi.org/10.1016/j.therap.2016.04.006.CrossRefPubMed

48.

Khalid Z, Hennen MA, Aldana-Bernier L. Gabapentin abuse by nasal insufflation: a case report. J Clin Psychopharmacol. 2019;39(1):89–91. https://doi.org/10.1097/JCP.0000000000000983.CrossRefPubMed

49.

Lupi M, Sepede G, Cinosi E, Martinotti G, di Giannantonio M. The efficacy of transcranical direct current stimulation in pregabalin abuse: a case report. J ECT. 2018;34(1):e14–5. https://doi.org/10.1097/YCT.0000000000000475.CrossRefPubMed

50.

Martinez GM, Olabisi J, Ruekert L, Hasan S. A call for caution in prescribing gabapentin to individuals with concurrent polysubstance abuse: a case report. J Psychiatr Pract. 2019;25(4):308–12.CrossRefPubMed

51.

Tcheremissine OV, Bestha DP. Gabapentin abuse in a patient with comorbid mood and substance use disorders. Innov Clin Neurosci. 2016;13(7–8):13–4.PubMedPubMedCentral

52.

Loudin S, Murray S, Prunty L, Davies T, Evans J, Werthammer J. An atypical withdrawal syndrome in neonates prenatally exposed to gabapentin and opioids. J Pediatr. 2017;181:286–8. https://doi.org/10.1016/j.jpeds.2016.11.004.CrossRefPubMed

53.

Aktaş S, Tetikoğlu M, İnan S, Aktaş H, Özcura F. Unilateral hemorrhagic macular infarction associated with marijuana, alcohol and antiepileptic drug intake. Cutan Ocul Toxicol. 2017;36(1):88–95. https://doi.org/10.3109/15569527.2016.1141420.CrossRefPubMed

54.

Guerrieri D, Rapp E, Roman M, Druid H, Kronstrand R. Postmortem and toxicological findings in a series of furanylfentanyl-related deaths. J Anal Toxicol. 2017;41(3):242–9. https://doi.org/10.1093/jat/bkw129.CrossRefPubMed

55.

Applewhite D, Regan S, Koenigs K, et al. Use of promethazine, gabapentin and clonidine in combination with opioids or opioid agonist therapies among individuals attending a syringe service program. Int J Drug Policy. 2020;79:10275.CrossRef

56.

Buttram ME, Kurtz SP. Descriptions of gabapentin misuse and associated behaviors among a sample of opioid (Mis)users in South Florida. J Psychoactive Drugs. 2020a. https://doi.org/10.1080/02791072.2020.1802087 ((Epub ahead of print)).CrossRefPubMedPubMedCentral

57.

Buttram ME, Kurtz SP, Cicero TJ, Havens JR. An ethnographic decision model of the initiation of gabapentin misuse among prescription and/or illicit opioid (mis)user. Drug Alcohol Depend. 2019;204:107554.CrossRefPubMedPubMedCentral

58.

Buttram ME, Kurtz SP. Preliminary evidence of pregabalin misuse among prescription and/or illicit opioid (mis)users. J Psychoactive Drugs. 2020b;52(2):172–5.CrossRefPubMedPubMedCentral

59.

Chatterjee A, Lopez D, Ramkellawan S, et al. “That’s what we call the cocktail”: non-opioid medication and supplement misuse among opioid users. Subst Abuse. 2019. https://doi.org/10.1080/08897077.2019.1671943 ((Epub ahead of print)).CrossRef

60.

Loudin S, Haas J, Payne M, et al. Identifying co-exposure to opiates and gabapentin during pregnancy. J Pediatr. 2020;217:196–8.CrossRefPubMed

61.

Thompson A, Morey S, Griffiths A. Pregabalin and its involvement in coronial cases. J Anal Toxicol. 2020;44:29–35.PubMed

62.

Torrance N, Veluchamy A, Zhou Y, et al. Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland. Br J Anaesth. 2020;125(2):159–67.CrossRefPubMed

63.

Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160–74.CrossRefPubMedPubMedCentral

64.

Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and withdrawal. Ann Pharmacother. 2016;50(3):229–33.CrossRefPubMed

65.

Quintero GC. Review about gabapentin misuse, interactions, contraindications and side effects. J Exp Pharmacol. 2017;9:13–21.CrossRefPubMedPubMedCentral

66.

Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. 2017;27(12):1185–215.CrossRefPubMed

67.

Warren B. Drug Touted as a safe alternative to painkillers has been found in more Louisville deaths. Louisville Courier Journal. March 26, 2018. https://www.courier-journal.com/story/news/crime/2018/03/26/gabapentin-overdose-deaths-louisville-fataladdiction/372489002/. Accessed 28 July 2019.

68.

Molero Y, Larsson H, D’Onofrio BM, Sharp DJ, Fazel S. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ. 2019;365:j2147. https://doi.org/10.1136/bmj.l2147.CrossRef

69.

Huybrechts KF, Bateman BT, Desai RJ, et al. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. BMJ. 2017;358:j3326. https://doi.org/10.1136/bmj.j3326.CrossRefPubMedPubMedCentral

70.

IQVIA Institute. https://www.iqvia.com/institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023. Accessed 27 Feb 2020.

71.

Quintiles IMS Institute. https://structurecms-staging-psyclone.netdna-ssl.com/client_assets/dwonk/media/attachments/590c/6aa0/6970/2d2d/4182/0000/590c6aa069702d2d41820000.pdf?1493985952. Accessed 3 May 2020.

72.

Hamer AM, Haxby DG, McFarland BH, Ketchum K. Gabapentin use in a managed Medicaid population. J Managed Care Pharm. 2002;8(4):266–71.CrossRef

73.

Peckham AM, Evoy KE, Ochs L, Covvey JR. Gabapentin for off-label use: evidence-based or cause for concern? Subst Abuse. 2018;12:1–8.

74.

Evoy KE, Leonard CE, Covvey JR, Ochs L, Peckham AM, Soprano S, Reveles KR. Receipt of substance use counseling among ambulatory patients prescribed opioids in the United States. Subst Abuse. 2020;14:1–4.

75.

Burns C. Pregabalin and gabapentin to be reclassified as Class C controlled substances. The Pharmaceutical Journal. 17 Oct 2018. https://www.pharmaceutical-journal.com/news-and-analysis/news/pregabalin-and-gabapentin-to-be-reclassified-as-class-c-controlled-substances/20205611.article. Accessed 3 May 2020.

Titel: Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update
verfasst von: Kirk E. Evoy
Sarvnaz Sadrameli
Jillian Contreras
Jordan R. Covvey
Alyssa M. Peckham
Megan D. Morrison
Publikationsdatum: 01.01.2021
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 1/2021
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-020-01432-7

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update

Abstract

Background

Objective

Methods

Results

Conclusion

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Correction to: Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma

Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer

50 Years On Still Relevant

50 Years of Drugs

Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing

Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis